Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide (RM-493) Treatment Trial in Patients with Rare Genetic Disorders of Obesity
2014-002392-28Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of setmelanotide in pro-opiomelanocortin deficiency and Adrenocorticotropic hormone, sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Body weight course before and with RM-493 treatment. Started Aug 2014; status: completed.
02
Drugs
setmelanotide
03
Conditions
pro-opiomelanocortin deficiencyAdrenocorticotropic hormone
Beyond the preview
Go deeper on 2014-002392-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002392-28.